Juan Garcia Valero

Citée par

	Toutes	Depuis 2020
Citations	584	409
indice h	13	11
indice i10	15	11

100

20112012201320142015201620172018201920202021202220232024202514 16 9 17 13 17 21 23 38 57 90 90 67 94 11

Accès public

Tout afficher

18 articles

2 articles

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Gaël RouéGroup leader, Josep Carreras Leukaemia Research InsituteAdresse e-mail validée de carrerasresearch.org
Vanina RodríguezThe Kinghorn Cancer Centre. Garvan InstituteAdresse e-mail validée de garvan.org.au
Jesús SalgadoProfessor of Biochemistry and Molecular Biology, University of ValenciaAdresse e-mail validée de uv.es
Laura MagnanoHospital Clínic de BarcelonaAdresse e-mail validée de clinic.ub.es
Diana GimenezResearch Fellow in Chemical Biology. University of BirminghamAdresse e-mail validée de leeds.ac.uk
Abdel AouacheriaISEM CNRS Université de MontpellierAdresse e-mail validée de umontpellier.fr
Anna Esteve-ArenysInstituto de Investigación Biomédica de SalamancaAdresse e-mail validée de usal.es
Alfredo Rivas-DelgadoMemorial Sloan Kettering Cancer CenterAdresse e-mail validée de mskcc.org
Martina Guerrero-HernándezCRG PhD Research TechnicianAdresse e-mail validée de crg.eu
Aranzazu Chamorro-JorganesImperial College LondonAdresse e-mail validée de imperial.ac.uk
Jean Luc CollINSERM-UGA U1209, CNRS UMR5309Adresse e-mail validée de univ-grenoble-alpes.fr
Lucie SanceyDR CNRS, Institute for Advanced Biosciences Grenoble, FranceAdresse e-mail validée de univ-grenoble-alpes.fr
Cèlia DobañoPostdoc fellow, DKFZ-HeidelbergAdresse e-mail validée de dkfz-heidelberg.de
Jean Jacques FourniéCentre de Recherches en Cancérologie de Toulouse, Universitré de Toulouse, PRESAdresse e-mail validée de inserm.fr
Ysebaert LoicHematologistAdresse e-mail validée de iuct-oncopole.fr
Cedric Rossi, MD, PhDStanford School Medicine, Hematology Department university hospital Dijon-Bourgogne France, INSERMAdresse e-mail validée de chu-dijon.fr
Ferran Araujo-AyalaPostdoctoral researcher, IDIBAPSAdresse e-mail validée de recerca.clinic.cat
Grzegorz RymkiewiczProfesor, Kierownik Pracowni, dr habilitowanyAdresse e-mail validée de pib-nio.pl
ANTONIO MARTINEZUniversidad de Barcelona, Hospital Clinic, IDIBAPSAdresse e-mail validée de clinic.cat
Joaquim CarrerasTokai University, School of Medicine, Department of PathologyAdresse e-mail validée de tokai-u.jp

Suivre

Juan Garcia Valero

CIBER Researcher at IDIBAPS (August Pi i Sunyer Biomedical Research Institute)

Adresse e-mail validée de recerca.clinic.cat - Page d'accueil

Cancer Apoptosis Bcl-2 Lymphoma Tumor microenvironment


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma A Esteve-Arenys, JG Valero, A Chamorro-Jorganes, D Gonzalez, ... Oncogene 37 (14), 1830-1844, 2018	93	2018
Bax-derived membrane-active peptides act as potent and direct inducers of apoptosis in cancer cells JG Valero, L Sancey, J Kucharczak, Y Guillemin, D Gimenez, J Prudent, ... Journal of cell science 124 (4), 556-564, 2011	70	2011
Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia N Giménez, A Martínez-Trillos, A Montraveta, M Lopez-Guerra, L Rosich, ... Haematologica 104 (3), 576, 2018	65	2018
The receptor of the colony-stimulating factor-1 (CSF-1R) is a novel prognostic factor and therapeutic target in follicular lymphoma JG Valero, A Matas-Céspedes, F Arenas, V Rodriguez, J Carreras, ... Leukemia, 2021	53	2021
Daratumumab displays in vitro and in vivo anti-tumor activity in models of B cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. A Vidal-Crespo, A Matas-Céspedes, V Rodriguez, C Rossi, JG Valero, ... Haematologica 104 (7), 2019	45	2019
PI3Kδ inhibition reshapes follicular lymphoma–immune microenvironment cross talk and unleashes the activity of venetoclax N Serrat, M Guerrero-Hernández, A Matas-Céspedes, A Yahiaoui, ... Blood advances 4 (17), 4217-4231, 2020	34	2020
Active fragments from pro-and antiapoptotic BCL-2 proteins have distinct membrane behavior reflecting their functional divergence Y Guillemin, J Lopez, D Gimenez, G Fuertes, JG Valero, L Blum, ... PloS one 5 (2), e9066, 2010	31	2010
Apaf-1 Inhibitors Protect from Unwanted Cell Death in In Vivo Models of Kidney Ischemia and Chemotherapy Induced Ototoxicity M Orzaez, M Sancho, S Marchan, L Mondragon, R Montava, JG Valero, ... PloS one 9 (10), e110979, 2014	29	2014
µ-Calpain conversion of antiapoptotic Bfl-1 (BCL2A1) into a prodeath factor reveals two distinct alpha-helices inducing mitochondria-mediated apoptosis JG Valero, A Cornut-Thibaut, R Juge, AL Debaud, D Gimenez, G Gillet, ... PloS one 7 (6), e38620, 2012	27	2012
A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses F Araujo-Ayala, C Dobaño-López, JG Valero, F Nadeu, F Gava, C Faria, ... Leukemia 37 (6), 1311-1323, 2023	23	2023
Follicular Lymphoma Microenvironment: An Intricate Network Ready for Therapeutic Intervention C Dobaño-López, F Araujo-Ayala, N Serrat, JG Valero, P Pérez-Galán Cancers 13 (4), 641, 2021	18	2021
Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma P Balsas, A Esteve-Arenys, J Roldán, L Jiménez, V Rodríguez, JG Valero, ... Journal of Hematology & Oncology 10, 1-14, 2017	17	2017
3D Model Characterization by 2D and 3D Imaging in t (14; 18)-Positive B-NHL: Perspectives for In Vitro Drug Screens in Follicular Lymphoma F Gava, C Faria, P Gravelle, JG Valero, C Dobaño-López, R Morin, ... Cancers 13 (7), 1490, 2021	16	2021
Lipidomic profile of GM95 cell death induced by Clostridium perfringens alpha-toxin MM Manni, JG Valero, M Pérez-Cormenzana, A Cano, C Alonso, FM Goñi Chemistry and physics of lipids 203, 54-70, 2017	13	2017
Lipid-dependent bimodal MCL1 membrane activity O Landeta, JG Valero, H Flores-Romero, I Bustillo-Zabalbeitia, ... ACS chemical biology 9 (12), 2852-2863, 2014	13	2014
Patient-derived lymphoma spheroids integrating immune tumor microenvironment as preclinical follicular lymphoma models for personalized medicine C Faria, F Gava, P Gravelle, JG Valero, C Dobaño-López, N Van Acker, ... Journal for Immunotherapy of Cancer 11 (10), e007156, 2023	7	2023
Cardiac fibroblasts display endurance to ischemia, high ROS control and elevated respiration regulated by the JAK2/STAT pathway A Beà, J García Valero, A Irazoki, C Lana, G López‐Lluch, M Portero‐Otín, ... The FEBS Journal, 2021	6	2021
Venetoclax improves CD20 immunotherapy in a mouse model of MYC/BCL2 double-expressor diffuse large B-cell lymphoma J Melchor, M Garcia-Lacarte, SC Grijalba, A Arnaiz-Leché, M Pascual, ... Journal for Immunotherapy of Cancer 11 (2), e006113, 2023	5	2023
Revised International Prognostic Index and genetic alterations are associated with early failure to R‐CHOP in patients with diffuse large B‐cell lymphoma I Dlouhy, K Karube, A Enjuanes, I Salaverria, F Nadeu, JE Ramis‐Zaldivar, ... British Journal of Haematology 196 (3), 589-598, 2022	5	2022
DECIPHERING THE CONTRIBUTION OF MACROPHAGES TO FOLLICULAR LYMPHOMA PATHOGENESIS: NEW INSIGHTS INTO THERAPY P Perez Galan, JG Valero, A Matas‐Cespedes, V Rodriguez, F Arenas, ... Hematological Oncology 37, 151-152, 2019	4	2019

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs